El papel de los biosimilares en la enfermedad inflamatoria intestinal: una realidad en nuestro país

Velásquez, Juan Ricardo Márquez; García, Fernando L. de la Vega

doi:10.22516/25007440.174

Cited by 1 publication

(6 citation statements)

References 34 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some cases, moreover, health systems do not cover all treatments, a fact which delays access to timely treatment. 28,51,52 On the other hand, the study carried out in Spain showed that indirect costs are very significant, representing 46.5% of total costs, and are mostly associated with productivity losses due to temporary absences from work and work disabilities. The analysis carried out estimated that more than 40% of active workers with IBD have been absent at some time in the last 3 months due to the disease and 10% of patients willing to have a full-time job, find involuntary part-time employees.…”

Section: Therapeutic Advances In Gastroenterologymentioning

confidence: 99%

“…48 Although in recent years there have been important advances in the diagnostic methods used, achieving a diagnosis at early stage of IBD continues to be one of the main challenges for the timely management of the disease. 15,47,52 Recent studies in Europe have revealed that in approximately 45% of cases, IBD patients take more than a year to receive a definitive diagnosis. 22 According to a similar study carried out in Brazil, where 3476 patients participated, only 30.25% of people were diagnosed within 6 months after presenting symptoms.…”

Section: Diagnosis and Management Of The Diseasementioning

confidence: 99%

“…Many of the patients in the region exceed the window of opportunity and the disease progresses to irreversible structural damage, further aggravating the economic impact for patients. [51][52][53][54][55][56][57] Once the diagnosis is confirmed, treatment and monitoring by the doctor are essential. The objectives are to calm the symptoms, heal the lesions when possible, and try to prevent the disease from reactivating.…”

Section: Diagnosis and Management Of The Diseasementioning

confidence: 99%

“…In some cases, moreover, health systems do not cover all treatments, a fact which delays access to timely treatment. 28 , 51 , 52 …”

Section: Incidence Prevalence and Burden Of The Diseasementioning

confidence: 99%

Section: Diagnosis and Management Of The Diseasementioning

confidence: 99%

See 4 more Smart Citations

Latin America consensus statement inflammatory bowel disease: importance of timely access to diagnosis and treatment

Steinwurz,

Machado,

Veitia

et al. 2023

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Inflammatory bowel diseases (IBDs) are chronic conditions that negatively interferes with the quality of life of the patients, on a physical, emotional, and social level. Its symptoms can vary including diarrhea, bleeding, abdominal pain, fever, and weight loss, depending on the type and location and severity of the disease. Despite evolving treatment, they do not always achieve control of the symptoms, so between 23% and 45% of people with idiopathic chronic ulcerative colitis, and up to 75% of those with Crohn’s disease, eventually, will need surgery. Objective: The increase in its incidence in Latin America has promoted a renewed interest on the part of the medical and scientific community in standardizing and unifying criteria for the proper diagnosis and management of the disease, which is part of the current discussions of various events; however, this interest has not yet been reflected in policies and initiatives by governments to address the disease. We decided to develop a consensus meeting in order to elucidate the actual situation of IBD care in our region. Design: The methodology employed to build the consensus document derived from a review of literature, evidence, and policies on IBD, followed by a process of validation and feedback with a group of 10 experts in the field. Methods: Nine experts from different countries in Latin America were reunited in web meetings on 2 days and voted on topics derived from the consensus document. A full agreement with 100% approval was needed, so topics were discussed to reach the consensus otherwise were removed. Results: There is still a lack of information about IBD in Latin America, therefore IBD continues to be an ‘invisible’ disease and is little recognized by decision-makers. Conclusion: This document describes the current situation of IBDs in the Latin American region, highlighting the main barriers and challenges in timely access to diagnosis and treatment, in order to demonstrate the need to promote the development and implementation of policies, in order to improve the quality of care of patients with IBD.

show abstract

Section: Therapeutic Advances In Gastroenterologymentioning

confidence: 99%

Section: Diagnosis and Management Of The Diseasementioning

confidence: 99%

Section: Diagnosis and Management Of The Diseasementioning

confidence: 99%

“…In some cases, moreover, health systems do not cover all treatments, a fact which delays access to timely treatment. 28 , 51 , 52 …”

Section: Incidence Prevalence and Burden Of The Diseasementioning

confidence: 99%